Bristol-Myers Shells Out $21M To Settle Orencia Suit
ZymoGenetics and Bristol-Myers disclosed the settlement agreement in filings with the U.S. Securities and Exchange Commission. The settlement resolves a suit Seattle-based ZymoGenetics filed against the pharmaceutical giant in 2006.
Under the terms of the agreement, Bristol-Myers will receive a nonexclusive, worldwide license to ZymoGenetics patents for fusion proteins in exchange for the...
To view the full article, register now.